PMID- 29471387
OWN - NLM
STAT- MEDLINE
DCOM- 20191104
LR  - 20220716
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 66
IP  - 12
DP  - 2018 Jun 1
TI  - Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune 
      Cell Frequencies in Antiretroviral Therapy-Treated Human Immunodeficiency 
      Virus-Infected Individuals.
PG  - 1872-1882
LID - 10.1093/cid/cix1116 [doi]
AB  - BACKGROUND: Cannabis is a widely used drug in the United States, and the 
      frequency of cannabis use in the human immunodeficiency virus (HIV)-infected 
      population is disproportionately high. Previous human and macaque studies suggest 
      that cannabis may have an impact on plasma viral load; however, the relationship 
      between cannabis use and HIV-associated systemic inflammation and immune 
      activation has not been well defined. METHODS: The impact of cannabis use on 
      peripheral immune cell frequency, activation, and function was assessed in 198 
      HIV-infected, antiretroviral-treated individuals by flow cytometry. Individuals 
      were categorized into heavy, medium, or occasional cannabis users or noncannabis 
      users based on the amount of the cannabis metabolite 
      11-nor-carboxy-tetrahydrocannabinol (THC-COOH) detected in plasma by mass 
      spectrometry. RESULTS: Heavy cannabis users had decreased frequencies of human 
      leukocyte antigen (HLA)-DR+CD38+CD4+ and CD8+ T-cell frequencies, compared to 
      frequencies of these cells in non-cannabis-using individuals. Heavy cannabis 
      users had decreased frequencies of intermediate and nonclassical monocyte 
      subsets, as well as decreased frequencies of interleukin 23- and tumor necrosis 
      factor-alpha-producing antigen-presenting cells. CONCLUSIONS: While the clinical 
      implications are unclear, our findings suggest that cannabis use is associated 
      with a potentially beneficial reduction in systemic inflammation and immune 
      activation in the context of antiretroviral-treated HIV infection.
FAU - Manuzak, Jennifer A
AU  - Manuzak JA
AD  - Department of Pharmaceutics, University of Washington.
AD  - Washington National Primate Research Center.
FAU - Gott, Toni M
AU  - Gott TM
AD  - Department of Pharmaceutics, University of Washington.
AD  - Washington National Primate Research Center.
FAU - Kirkwood, Jay S
AU  - Kirkwood JS
AD  - Department of Pharmaceutics, University of Washington.
FAU - Coronado, Ernesto
AU  - Coronado E
AD  - Department of Pharmaceutics, University of Washington.
AD  - Washington National Primate Research Center.
FAU - Hensley-McBain, Tiffany
AU  - Hensley-McBain T
AD  - Department of Pharmaceutics, University of Washington.
AD  - Washington National Primate Research Center.
FAU - Miller, Charlene
AU  - Miller C
AD  - Department of Pharmaceutics, University of Washington.
AD  - Washington National Primate Research Center.
FAU - Cheu, Ryan K
AU  - Cheu RK
AD  - Department of Pharmaceutics, University of Washington.
AD  - Washington National Primate Research Center.
FAU - Collier, Ann C
AU  - Collier AC
AD  - Department of Medicine, Harborview Medical Center, University of Washington, 
      Seattle.
FAU - Funderburg, Nicholas T
AU  - Funderburg NT
AD  - School of Health and Rehabilitation Sciences, Division of Medical Laboratory 
      Science, College of Medicine, Ohio State University, Columbus.
FAU - Martin, Jeffery N
AU  - Martin JN
AD  - Department of Epidemiology and Biostatistics, University of California, San 
      Francisco.
FAU - Wu, Michael C
AU  - Wu MC
AD  - Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle, 
      Washington.
FAU - Isoherranen, Nina
AU  - Isoherranen N
AD  - Department of Pharmaceutics, University of Washington.
FAU - Hunt, Peter W
AU  - Hunt PW
AD  - Department of Medicine, University of California, San Francisco.
FAU - Klatt, Nichole R
AU  - Klatt NR
AD  - Department of Pharmaceutics, University of Washington.
AD  - Washington National Primate Research Center.
LA  - eng
GR  - DP1 DA037979/DA/NIDA NIH HHS/United States
GR  - P30 AI027763/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 0 (Anti-HIV Agents)
RN  - 4TPC9E4A32 (11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid)
RN  - 7J8897W37S (Dronabinol)
SB  - IM
MH  - Anti-HIV Agents/*therapeutic use
MH  - Antiretroviral Therapy, Highly Active
MH  - CD4-Positive T-Lymphocytes/drug effects
MH  - CD8-Positive T-Lymphocytes/drug effects
MH  - Dronabinol/analogs & derivatives/blood
MH  - Female
MH  - Flow Cytometry
MH  - HIV Infections/*drug therapy
MH  - Humans
MH  - Immunity, Innate/*drug effects
MH  - Inflammation
MH  - Lymphocyte Activation/*drug effects
MH  - Male
MH  - Marijuana Abuse/*immunology
MH  - Middle Aged
MH  - Monocytes/drug effects
MH  - Viral Load/drug effects
PMC - PMC6248381
EDAT- 2018/02/23 06:00
MHDA- 2019/11/05 06:00
PMCR- 2019/06/15
CRDT- 2018/02/23 06:00
PHST- 2017/09/21 00:00 [received]
PHST- 2017/12/22 00:00 [accepted]
PHST- 2018/02/23 06:00 [pubmed]
PHST- 2019/11/05 06:00 [medline]
PHST- 2018/02/23 06:00 [entrez]
PHST- 2019/06/15 00:00 [pmc-release]
AID - 4869752 [pii]
AID - cix1116 [pii]
AID - 10.1093/cid/cix1116 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2018 Jun 1;66(12):1872-1882. doi: 10.1093/cid/cix1116.